Synonyms: (2'R)-Adipoyldi-D-proline; (R)-1-[6-[(R)-2-Carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl-]pyrrolidine-2-carboxylic acid; 1,1'-(1,6-Dioxo-1,6-hexanediyl)bis[D-proline]; GSK 2315698; GSK-2315698; GSK2315698; Miridesap; R-1-[6-[R-2-carboxy-pyrrolidin-1-yl]-6-oxohexanoyl]pyrrolidine-2-carboxylic acid; Ro 63-8695; Ro-63-8695
Molecular Formula: C16H24N2O6
Molecular Weight: 340.37
Linear Structural Formula: C16H24N2O6
MDL Number: MFCD09970762
Purity: >=98% (HPLC)
Storage: -20C
Biochem Physiol Actions: CPHPC (Miridesap; Ro 63-8695) is an orally active serum amyloid P (SAP) blocker that targets the ligand-binding site on the SAP planar binding (B) face with each of its two D-proline moieties (up to two SAP per CPHPC), being able to crosslink and dimerize two SAP pentamers to form B face-to-B face decamers. CPHPC potently inhibits SAP binding to amyloid fibrils in vitro (IC50 = 0.9 muM using AD Abeta amyloid fibrils) and exhibits in vivo efficacy toward liver & circulating SAP clearance as well as SAP removal from tissue amyloid deposits (1-5 mg/mL in drinking water; human SAP transgenic mice).